Abstract

Intravenous (IV) tissue-type plasminogen activator (tPA) is the only approved noninvasive therapy for acute ischemic stroke (AIS). However, after tPA treatment, the outcome of patients with different subtypes of stroke according to their vascular risk factors remains to be elucidated. We aim to explore the relationship between the outcome and different risk factors in patients with different subtype of acute strokes treated with IV tPA. Records of patients in this cohort were reviewed. Data collected and analysed included the demographics, vascular risk factors, baseline National Institutes of Health Stroke Scale (NIHSS) scores, 90-day modified Rankin Scores (mRS), and subtypes of stroke. By using the 90-day mRS, patients were dichotomized into favorable versus unfavorable outcome in each subtype of stroke. We identified the vascular risk factors that are likely associated with the poor outcome in each subtype. Among 570 AIS patients received IV tPA, 217 were in the large artery atherosclerosis (LAA) group, 146 in the small vessel occlusion(SVO) group, and 140 in the cardioaortic embolism(CE) group. Lower NIHSS score on admission was related to favorable outcome in patients in all subtypes. Patients with history of dyslipidemia were likely on statin treatment before their admission and hence less likely to have elevated cholesterol level on admission. Therefore, there was a possible paradoxical effect on the outcome in patients with LAA and SVO subtypes of strokes. SVO patients with history of diabetes had higher risk of unfavorable outcome. SVO patients had favorable outcome if their time from onset to treatment was short. In conclusion, the outcome of patients treated with IV tPA may be related to different vascular risk factors associated with different subtypes of stroke.

Highlights

  • Tissue-type plasminogen activator is the only approved intravenous (IV) therapy for acute ischemic stroke (AIS) [1]

  • We evaluated factors that may affect the outcome post IV type plasminogen activator (tPA) in patients with different subtypes of stroke associated with different risk factors, their stroke severity and onset to treatment time (OTT)

  • We identified all patients with AIS who received IV tPA only at OSF Saint Francis Medical Center, a Joint Commission certified Comprehensive Stroke Center (CSC) in Peoria, Illinois between March 2010 and October 2013

Read more

Summary

Introduction

Tissue-type plasminogen activator (tPA) is the only approved intravenous (IV) therapy for acute ischemic stroke (AIS) [1]. Other studies have examined only the risk factors that may influence the outcome post IV tPA but did not study further to look into the influence of each subtype of stroke with the risk factors on the outcome. In these studies, diabetes mellitus have been identified as a common risk factor associated with unfavorable outcome.[8] it remains unclear if different subtypes of stroke with different severity and associated risk factors would have similar outcome post IV tPA treatment. We evaluated factors that may affect the outcome post IV tPA in patients with different subtypes of stroke associated with different risk factors, their stroke severity and onset to treatment time (OTT)

Objectives
Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call